Compare KWR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | BEAM |
|---|---|---|
| Founded | 1918 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 1994 | 2019 |
| Metric | KWR | BEAM |
|---|---|---|
| Price | $120.92 | $25.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $152.50 | $49.13 |
| AVG Volume (30 Days) | 156.2K | ★ 1.7M |
| Earning Date | 05-26-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,888,634,000.00 | $24,000.00 |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $4.03 | $35.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.66 | ★ 33.33 |
| 52 Week Low | $95.91 | $13.53 |
| 52 Week High | $183.01 | $36.44 |
| Indicator | KWR | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 18.27 | 42.32 |
| Support Level | $111.56 | $23.84 |
| Resistance Level | $126.57 | $25.69 |
| Average True Range (ATR) | 7.41 | 1.94 |
| MACD | -3.77 | -0.23 |
| Stochastic Oscillator | 0.00 | 9.58 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.